ID   VOA1312
AC   CVCL_V538
SY   VOA1312_CL; VOA-1312; VOA 1312
DR   cancercelllines; CVCL_V538
DR   Wikidata; Q54993302
RX   DOI=10.14288/1.0319145;
RX   PubMed=24023729;
RX   PubMed=27822414;
RX   PubMed=28545687;
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=27822414).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): PubMed=27822414
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 9,12
ST   D16S539: 9,12
ST   D21S11: 29
ST   D5S818: 12
ST   D7S820: 8,11
ST   TH01: 7,9
ST   TPOX: 10,11
ST   vWA: 17,19
DI   NCIt; C105556; Low grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 19-12-24; Version: 9
//
RX   DOI=10.14288/1.0319145;
RA   Dawson A.;
RT   "Targeted therapy in low-grade serous ovarian carcinoma:
RT   characterization of MEK inhibitor response in novel patient-derived
RT   cell lines.";
RL   Thesis PhD (2016); University of British Columbia; Vancouver; Canada.
//
RX   PubMed=24023729; DOI=10.1371/journal.pone.0072162; PMCID=PMC3762837;
RA   Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M.,
RA   Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R.,
RA   Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.;
RT   "Type-specific cell line models for type-specific ovarian cancer
RT   research.";
RL   PLoS ONE 8:e72162.1-e72162.13(2013).
//
RX   PubMed=27822414; PMCID=PMC5088288;
RA   Fernandez M.L., DiMattia G.E., Dawson A., Bamford S., Anderson S.,
RA   Hennessy B.T., Anglesio M.S., Shepherd T.G., Salamanca C.M.,
RA   Hoenisch J., Tinker A., Huntsman D.G., Carey M.S.;
RT   "Differences in MEK inhibitor efficacy in molecularly characterized
RT   low-grade serous ovarian cancer cell lines.";
RL   Am. J. Cancer Res. 6:2235-2251(2016).
//
RX   PubMed=28545687; DOI=10.1016/j.ygyno.2017.05.019;
RA   Mert I., Chhina J., Allo G., Dai J., Seward S., Carey M.S.,
RA   Llaurado M., Giri S., Rattan R., Munkarah A.R.;
RT   "Synergistic effect of MEK inhibitor and metformin combination in low
RT   grade serous ovarian cancer.";
RL   Gynecol. Oncol. 146:319-326(2017).
//